The CIMT trial, unlike other metformin trials, did not consider cardiovascular risk factors and included type 2 diabetics treated with OHAs for at least a year or insulin for 3 months, excluding those with over 70% carotid artery stenosis. Here, INS is linked to coronary atherosclerosis measurement.